The challenge of non-motor symptoms in Parkinson's disease

Progress in Brain Research

Volumn 184, Issue C, 2010, Pages 325-341

  Chaudhuri, K Ray ^a   Odin, Per ^b,c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Department of Neurology   (Germany)

Author keywords

Non motor; Non motor symptoms quest; Non motor symptoms scale; Parkinson's disease; Rating scales

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; CLONAZEPAM; CLOZAPINE; DONEPEZIL; FLUVOXAMINE; LEVODOPA; MODAFINIL; NEUROLEPTIC AGENT; PRAMIPEXOLE; QUETIAPINE; RIVASTIGMINE; SELEGILINE; SILDENAFIL;

ANXIETY DISORDER; AUTONOMIC DYSFUNCTION; BOOK; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DAYTIME SOMNOLENCE; DEMENTIA; DOPAMINERGIC SYSTEM; DYSAUTONOMIA; ERECTILE DYSFUNCTION; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSALIVATION; LEWY BODY; MENTAL DISEASE; MILD COGNITIVE IMPAIRMENT; NONHUMAN; OLFACTORY NERVE DISEASE; PAIN; PARKINSON DISEASE; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; SENSORY DYSFUNCTION; SEXUAL DYSFUNCTION; SLEEP DISORDER; VISUAL HALLUCINATION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 77957232523     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(10)84017-8     Document Type: Chapter

References (123)

1. Aarsland D., Andersen K., Larsen J.P., Perry R., Wentzel-Larsen T., Lolk A., et al. The rate of cognitive decline in Parkinson disease. Archives of Neurology 2004, 61(12):1906-1911.
2. Aarsland D., Larsen J.P., Lim N.G., Janvin C., Karlsen K., Tandberg E., et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 1999, 67:492-496.
3. Aarsland D., Larsen J.P., Tandberg E., Laake K. Predictors of nursing home placement in Parkinson's disease: A population-based, prospective study. Journal of American Geriatric Society 2000, 48(8):938-942.
4. Abbott R.D., Petrovitch H., White L.R., Masaki K.H., Tanner C.M., Curb J.D., et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001, 57(3):456-462.
5. Adler C.H., Caviness J.N., Hentz J.G., Lind M., Tiede J. Randomised trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Movement Disorders 2003, 18:287-293.
6. Alves G., Wentzel-Larsen T., Larsen J.P. Is fatigue an independent and persistent symptom in patients with Parkinson disease?. Neurology 2004, 10:1908-1911.
7. Ansari K.A., Johnson A. Olfactory function in patients with Parkinson's disease. Journal of Chronic Diseases 1975, 28(9):493-497.
8. Apaydin H., Ahlskog E., Parisi J.E., Boeve B.F., Dickson D.W. Parkinson disease neuropathology: Late-developing dementia and loss of the levodopa response. Archives of Neurology 2002, 59:102-112.
9. Arnulf I., Konofal E., Merino-Andreu M., Houeto J.L., Mesnage V., Welter M.L., et al. Parkinson's disease and sleepiness - an integral part of PD. Neurology 2002, 58:1019-1024.
10. Barone P., Antonini A., Colosimo C., Marconi R., Morgante L., Avarello T.P., et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Movement Disorders 2009, 24:1641-1649.
11. Benarroch E.E. Central neurotransmitters and neuromodulators in cardiovascular regulation. Autonomic failure 1999, 37-44. Oxford University Press, Oxford, UK. 4th Ed. C.J. Mathias, R. Bannister (Eds.).
12. Berendse H.W. Early diagnosis in PD: Olfaction. Parkinsonism and Related Disorders 2006, 12(1):1-2.
13. Boeve B.F., Silber M.H., Ferman T.J., Lucas J.A., Parisi J.E. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Movement Disorders 2001, 16:622-630.
14. Braak H., Del Tredici K., Rüb U., de Vos R.A.I., Jansen Steur E.N.H., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology Aging 2003, 24:197-210.
15. Braune S., Reinhardt M., Schnitzer R., Riedel A., Lücking C.H. Cardiac uptake of [123I] MIBG separates Parkinson's disease from multiple systems atrophy. Neurology 1999, 53:1020-1025.
16. Brown R.G., Jahanshahi M., Quinn N., Marsden C.D. Sexual function in patients with Parkinson's disease and their partners. Journal of Neurology, Neurosurgery and Psychiatry 1990, 53:480-486.
17. Brown R.G., Pluck G. Negative symptoms: the 'pathology' of motivation and goal directed behaviour. Trends in Neurosciences 2000, 23(9):412-417.
18. Burn D.J. Beyond the iron mask; towards better recognition and treatment of depression associated with Parkinson's disease. Movement Disorders 2002, 17:445-454.
19. Byrne R., Chaudhuri K.R. Depression a key nonmotor symptom of Parkinson's disease. Progress in Neurology and Psychiatry 2006, 10(5):15-21.
20. Castelli L., Perozzo P., Zibetti M., Crivelli B., Morabito U., Lanotte M., et al. Chronic deep brain stimulation of the subthalamic nucleus for Parkinson's disease: Effects on cognition, mood, anxiety and personality traits. European Neurology 2006, 55(3):136-144.
21. Cersosimo M.G., Benarroch E.E. Neural control of the gastrointestinal tract: implications for Parkinson disease. Movement Disorders 2008, 23(8):1065-1075.
22. Chaudhuri K.R. Autonomic dysfunction in movement disorders. Current Opinion in Neurology 2001, 14:505-511.
23. Chaudhuri K.R. Nocturnal symptom complex in PD and its management. Neurology 2003, 61(3):S17-S23.
24. Chaudhuri K.R., Healy D.G., Schapira A.H. Non-motor symptoms of Parkinson's disease: Diagnosis and management. Lancet Neurology 2006, 5(3):235-245.
25. Chaudhuri K.R., Martinez-Martin P. Quantitation of non motor symptoms of PD. European Journal of Neurology 2008, 15(Suppl 2):1-7.
26. Chaudhuri K.R., Martinez-Martin P., Brown R.G., Sethi K., Stocchi F., Odin P., et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Movement Disorders 2007, 22:1901-1911.
27. Chaudhuri K.R., Martinez-Martin P., Schapira A.H.V., Stocchi F., Sethi K., Odin P., et al. An international multicentre pilot study of the first comprehensive self-completed non-motor symptoms questionnaire for Parkinson's disease: The NMSQuest study. Movement Disorders 2006, 21(7):916-923.
28. Chaudhuri K.R., Prieto-Juvcynska C., Naidu Y., Mitra T., Frades-payo B., Tluk S., et al. The non-declaration of non-motor symptoms of Parkinson's disease to healthcare professionals. An international survey using the NMSQuest. Movement Disorders 2010, 25(6):697-701.
29. Chaudhuri K.R., Schapira A.H. Non-motor symptoms of Parkinson's disease: Dopaminergic pathophysiology and treatment. Lancet Neurology 2009, 8:464-474.
30. Clarimon J., Pagonabarraga J., Paisan-Ruiz C., Campolongo A., Pascual-Sedano B., Marti-Masso J.-F., et al. Tremor dominant parkinsonism: Clinical description and LRRK 2 mutation screening. Movement Disorders 2008, 23:518-523.
31. Corrigan M.H., Denahan A.Q., Wright C.E., Ragual R.J., Evans D.L. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depression Anxiety 2000, 11(2):58-65.
32. Del Tredici K., Braak H. Idiopathic Parkinson's disease: Staging an α-synucleinopathy with a predictable pathoanatomy. In. Molecular mechanisms in Parkinson's disease 2004, 1-32. Landes Bioscience, Georgetown, TX. P. Kahle, C. Haass (Eds.).
33. Dhawan V., Healy D.G., Pal S., Chaudhuri K.R. Sleep-related problems of Parkinson's disease. Age Ageing 2006, 35(3):220-228.
34. Diederich N.J., Goetz C.G., Stebbins G.T. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: Focused review and a new integrative model. Movement Disorders 2005, 20:130-140.
35. Diederich N.J., Pieri V., Hipp G., Rufra O., Blyth S., Vaillant M. Discriminative power of different nonmotor signs in early Parkinson's disease. A case-control study (p NA). Movement Disorders 2010, Epub ahead of print.
36. Doty R.L., Stern M.B., Pfeiffer C., Gollomp S.M., Hurtig H.I. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 1992, 55(2):138-142.
37. Eichhorn T.E., Oertel W.H. Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy. Movement Disorders 2001, 16:1176-1177.
38. 123 I-MIBG scintigraphy of catecholamine systems: impediments to applications in clinical medicine. European Journal of Nuclear Medicine and Molecular Imaging 2000, 27(5):611-612.
39. Eisensehr I., Linke R., Noachtar S., Schwarz J., Gildehaus F.J., Tatsch K. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls. Brain 2000, 123:1155-1160.
40. Emre M. Dementia associated with Parkinson's disease. Lancet Neurology 2003, 2(4):229-237.
41. Emre M., Aarsland D., Albanese A., Byrne E.J., Deuschl G., De Deyn P.P., et al. Rivastigmine for dementia associated with Parkinson's disease. New England Journal of Medicine 2004, 351:2509-2518.
42. Factor S.A., Brown D. Clozapine prevents recurrence of psychosis in Parkinson's disease. Movement Disorders 1992, 7(2):1125-1231.
43. Factor S., Friedman J.H., Lannon M.C., Oakes D., Bourgeois K. Clozapine for treatment of drug-induced psychosis in Parkinson's disease: Results of the 12-week open label extension in the PSYCLOPS trial. Movement Disorders 2001, 16:135-139. Parkinson Study Group.
44. Fenelon G., Mahieux F., Huon R., Ziegler M. Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors. Brain 2000, 123:733-745.
45. Findley L., Aujla M., Bain P.G., Baker M., Beech C., Bowman C., et al. Direct economic impact of Parkinson's disease: A research survey in the United Kingdom. Movement Disorders 2003, 18(10):1139-1145.
46. Garcia-Borreguero D., Larosa O., Bravo M. Parkinson's disease and sleep. Sleep Medicine Review 2003, 7:115-129.
47. Factors impacting on quality of life in Parkinson's disease: Results from an international survey. Movement Disorders 2002, 17(1):60-67. Global Parkinson's disease Survey Steering Committee.
48. Goetz C.G., Tanner C.M., Levy M., Wilson R.S., Garron D.C. Pain in Parkinson's disease. Movement Disorders 1986, 1(1):45-49.
49. Haq I., Naidu Y., Reddy P., Chaudhuri K.R. Narcolepsy in Parkinson's disease. Expert Reviews in Pharmacotherapy 2010, 10(6):879-884.
50. Hawkes C. Olfaction in neurodegenerative disorders. Movement Disorders 2003, 18:364-372.
51. Hely M.A., Morris J.G.L., Reid W.G.J., Trafficante R. Sydney multicenter study of Parkinson's disease: Non-L-dopa-responsive problems dominate at 15 years. Movement Disorders 2005, 20:190-199.
52. Hely M.A., Reid W.G., Adena M.A., Halliday G.M., Morris J.G. The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. Movement Disorders 2008, 23(6):837-844.
53. Henderson M., Lu Y., Wang S., Cartwright H., Halliday G.M. Olfactory deficits and sleep disturbances in Parkinson's disease: A case-control survey. Journal of Neurology, Neurosurgery and Psychiatry 2003, 74:956-958.
54. Herlofson K., Larsen J.P. The influence of fatigue on health related quality of life in patients with Parkinson's disease. Acta Neurologica Scandinavica 2003, 107(1):1-6.
55. Hogl B., Saletu B., Brandauer E., Gltzl S., Frauscher B., Seppi K., et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: A double blind, randomised, crossover, placebo controlled, polygraphic trial. Sleep 2002, 25(8):905-909.
56. Honig H., Antonini A., Martinez-Martin P., Forgacs I., Faye G.C., Fox T., et al. Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life. Movement Disorders 2009, 24:1468-1474.
57. Kalteis K., Standhartdt H., Kryspin-Exner I., Brucke T., Volt D., Ales F. Influence of bilateral Stn-stimulation on psychiatric symptoms and psychosocial functioning in patients with Parkinson's disease. Journal of Neural Transmission 2005, 113(9):1191-1206.
58. Karlsen K., Larsen J.P., Tandberg E., Jorgensen K. Fatigue in patients with Parkinson's disease. Movement Disorders 1999, 14:237-241.
59. Khan N.L., Katzenschlager R., Watt H., Bhatia K.P., Wood N.W., Quinn N., et al. Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease. Neurology 2004, 62(7):1224-1226.
60. Kipps C.M., Fung V.S.C., Grattan-Smith P., de Moore G.M., Morris J.G.L. Movement disorder emergencies. Movement Disorders 2005, 20:322-334.
61. Laakso M.P., Partanen K., Riekkinen P., Lehovirta M., Helkala E.L., Hallikainen M., et al. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with or without dementia: an MRI study. Neurology 1996, 46:678-681.
62. Lagalla G., Millevolte M., Capecci M., Provinciali L., Ceravolo M.G. Botulinum toxin type A for drooling in Parkinson's disease: A double blind, randomized, placebo-controlled study. Movement Disorders 2006, 21:704-707.
63. Lai Y.Y., Siegel J.M. Muscle tone suppression and stepping produced by stimulation of midbrain and rostral pontine reticular formation. Journal of Neuroscience 1990, 10(8):2727-2734.
64. Lauterbach E.C. The neuropsychiatry of Parkinson's disease and related disorders. Psychiatry Clinics in North America 2004, 27(4):801-825.
65. Lauterbach E.C., Freeman A., Vogel R.L. Differential DSM-III psychiatric disorder prevalence profiles in dystonia and Parkinson's disease. Journal of Neuropsychiatry and Clinical Neuroscience 2004, 16:29-36.
66. Lees A.J., Blackburn N.A., Campbell V.L. The nighttime problems of Parkinson's disease. Clinical Neuropharmacology 1988, 11:512-519.
67. Lerner A., Bagic A. Olfactory pathogenesis of idiopathic Parkinson's disease revisited. Movement Disorders 2008, 23:1076-1084.
68. Lou J.S. Physical and mental fatigue in Parkinson's disease: Epidemiology, pathophysiology and treatment. Drugs Aging 2009, 26(3):195-208.
69. MacMahon D. Why excessive daytime sleepiness is an important issue in Nonmotor symptoms in Parkinson's disease: An underdiagnosed problem - REVIEW Parkinson's disease. Advances in Clinical Neurology and Rehabilitation 2005, 5(2):46-49.
70. Magerkurth C., Schnitzer R., Braune S. Symptoms of autonomic failure in Parkinson's disease: Prevalence and impact on daily life. Clinical Autonomic Research 2005, 15:76-82.
71. Martinez-Martin P., Rodriguez-Blazquez C., Abe K., Bhattacharyya K.B., Bloem B.R., Carod-Artal J., et al. International study on the psychometric attributes of the non-motor symptoms scale in Parkinson's disease. Neurology 2009, 73:1584-1591.
72. Martinez-Martin P., Schapira A.H., Stocchi F., Sethi K., Odin P., MacPhee G., et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Movement Disorders 2007, 22(11):1623-1629.
73. Mattila P.M., Rinne J.O., Helenius H., Dickson D.W., Röytt M. α-Synuclein immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathologica 2000, 100:285-290.
74. Metta V., Rizos A., Chaudhuri K.R. Non-motor symptoms and Parkinson's disease. Advances in Clinical Neuroscience and Rehabilitation 2010, 10(1):19-21.
75. Montgomery E.B., Baker K.B., Lyons K., Koller W.C. Abnormal performance on the PD test battery by asymptomatic first-degree relatives. Neurology 1999, 52:757-762.
76. Montgomery E.B., Lyons K., Koller W.C. Early detection of probable idiopathic Parkinson's disease: II. A prospective application of diagnostic test battery. Movement Disorders 2000, 15:474-478.
77. Moskovitz C., Moses H., Klawans H.L. Levodopa-induced psychosis: A kindling phenomenon. American Journal of Psychiatry 1978, 135:669-675.
78. Muzerengi S., Contrafatto D., Chaudhuri K.R. Non-motor symptoms: identification and management. Parkinsonism Related Disorders 2007, 13(Suppl. 3):S450-456.
79. Nilsson F.M., Kessig L.V., Bolwig T.G. Increased risk of developing Parkinson's disease for patients with major affective disorders. Acta Psychiatrica Scandinavica 2001, 104:380-386.
80. Ondo W.G., Fayle R., Atassi F., Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: Double blind, placebo controlled parallel trial. Journal of Neurology, Neurosurgery and Psychiatry 2005, 76(12):1636-1639.
81. Olson E.J., Boeve B.F., Silber M.H. Rapid eye movement sleep behaviour disorder: Demographic, clinical and laboratory findings in 93 cases. Brain 2000, 123:331-339.
82. Ondo W.G., Tintner R., Vuong Dat K., Lai D., Ringholz G. Double blind placebo controlled unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Movement Disorders 2005, 20:958-963.
83. Onofrj M., Thomas A., D'Andreamatteo G., Iacono D., Luciano A.L., Di Rollo A., et al. Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up. Neurological Sciences 2002, 23:S91-S94.
84. O'Suilleabhain P.E., Sung V., Hernandez C., Lacritz L., Dewey R.B., Bottiglieri T., et al. Elevated plasma homocysteine level in patients with Parkinson disease: Motor, affective, and cognitive associations. Archives of Neurology 2004, 61:865-868.
85. O'Sullivan S.S., Williams D.R., Gallagher D.A., Massey L.A., Silveira-Moriyama L., Lees A.J. Nonmotor symptoms as presenting complaints in Parkinson's disease: A clinicopathological study. Movement Disorders 2008, 23:101-106.
86. Pålhagen S., Qi H., Mårtensson B., Wålinder J., Granérus A.K., Svenningsson P. Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression. Journal of Neurology 2010, 257:524-532.
87. Parsons T.D., Rogers S.A., Braaten A.J., Woods S.P., Troster A.I. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: A meta analysis. Lancet Neurology 2006, 5:578-588.
88. Pavese N., Metta V., Bose S., Chaudhuri K.R., Brooks D. Fatigue in Parkinson's disease is associated with reduced brain serotonin and dopamine innervations. Neurology 2010, 74(9 Suppl 2):A298-299.
89. Pezzella F.R., Colosimo C., Vanacore N., Di Rezze S., Chianese M., Fabbrini G. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Movement Disorders 2005, 20(1):77-81.
90. Pluck G.C., Brown R.G. Apathy in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 2002, 73:636-642.
91. Ponsen M.M., Stoffers D., Booij J., van Eck-Smit B.L., Wolters E.Ch., Berendse H.W. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Annals of Neurology 2004, 56(2):173-181.
92. Postuma R.B., Gagnon J.F., Rompr S., Montplaisir J.Y. Severity of REM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease. Neurology 2010, 74(3):239-244.
93. Postuma R.B., Lang A.E., Massicotte-Marquez J., Montplaisir J. Potential early markers of Parkinson's disease in idiopathic REM sleep behaviour disorder. Neurology 2006, 66(6):796-797.
94. Quinn N.P., Koller W.C., Lang A.E., Marsden C.D. Painful Parkinson's disease. Lancet 1996, 1(8494):1366-1369.
95. Raffaele R., Vecchio I., Giammuso B., Morgia G., Brunetto M.B., Rampello L. Efficacy and safety of fixed dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. European Urology 2002, 41(4):382-386.
96. Ravina B., Putt M., Siderowf A., Farrar J.T., Gillespie M., Crawley A., et al. Donezepil for dementia in Parkinson's disease: A randomised double blind, placebo controlled, crossover study. Journal of Neurology, Neurosurgery and Psychiatry 2005, 76(7):934-939.
97. Rektorova I., Rektor I., Bares M., Dostal V., Ehler E., Fanfrdlova Z., et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: A national multicentre prospective randomized study. European Journal of Neurology 2003, 10(4):399-406.
98. Remy P., Doder M., Lees A., Turjanski N., Brooks D. Depression in Parkinson's disease: Loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005, 128(Pt 6):1314-1322.
99. Reuter J., Raedler T., Rose M. Pathological gambling is linked to reduced activation in the mesolimbic reward system. Nature Neuroscience 2005, 8(2):147-148.
100. Richard I.H. Anxiety disorders in Parkinson's disease. Advances in Neurology 2005, 96:42-55.
101. Ross W., Petrovitch H., Abbott R.D., Tanner C.M., Popper J., Masaki K., et al. Association of olfactory dysfunction with risk of future Parkinson's disease. Movement Disorder 2005, 20(Suppl. 10):439. (abstract).
102. Rye D.B., Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology 2002, 58:341-346.
103. Saper C., Chou T.C., Scammell T.E. The sleep switch: Hypothalamic control of sleep and wakefulness. Trends in Neurosciences 2001, 24:726-731.
104. Schenck C.H., Bundlie S.R., Mahowald M.W. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology 1996, 46:388-393.
105. Scherder E. Pain in Parkinson's disease. Parkinson's disease-related cognitive dysfunction. Parkinsonism and Related Disorders 2006, 12(1):2.
106. Schrag A., Jahanshahi M., Quinn N. What contributes to quality of life in patients with Parkinson's disease?. Journal of Neurology, Neurosurgery and Psychiatry 2000, 69(3):308-312.
107. Schurmann A.G., Van den Akker H., Ensinck K.T.J.L., Metsemakers F.H., Knottnerus J.A., Leentjens F.G., et al. Increased risk of Parkinson's disease after depression: A retrospective cohort study. Neurology 2002, 58:1501-1504.
108. Shiba M., Bower J.H., Maraganore D.M., McDonnel S.K., Peterson B.J., Ahlskog J.E., et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: A case-control study. Movement Disorders 2000, 15:669-677.
109. Shulman L.M., Taback R.L., Rabinstein A.A., Weiner W.J. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism and Related Disorders 2002, 8:193-197.
110. Siderowf A., Jdennings D., Connolly J., Doty R., Mareck K., Stern M. Risk factors for Parkinson's disease and impaired olfaction in relatives of patients with Parkinson's disease. Movement Disorders 2007, 22:2249-2255.
111. Singh A., Althoff R., Martineau J., Jacobson J. Pramipexole, ropinirole, and mania in Parkinson's disease. American Journal of Psychiatry 2005, 162:814-815.
112. Starkstein S.E., Mayberg S.E., Preziosi T.J., Andrezejewski P., Leiguarda R., Robinson R.G. Reliability, validity and clinical correlates of apathy in Parkinson's disease. Journal of Neuropsychiatry 1992, 4:134-139.
113. Stiasny-Kolster K., Doerr Y., Moller J.C., Hoffken H., Behr T.M., Oertel W.H., et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005, 128(Pt 1):126-137.
114. Thanvi B.R., Munshi S.K., Vijaykumar N., Lo T.C. Neuropsychiatric non-motor aspects of Parkinson's disease. Postgraduate Medicine Journal 2003, 79(936):561-565.
115. Thobois S., Ardouin C., Lhommée E., Klinger H., Lagrange C., Xie J., Fraix V., Coelho Braga M.C., Hassani R., Kistner A., Juphard A., Seigneuret E., Chabardes S., Mertens P., Polo G., Reilhac A., Costes N., LeBars D., Savasta M., Tremblay L., Quesada J.L., Bosson J.L., Benabid A.L., Broussolle E., Pollak P., Krack P. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: Predictors and underlying mesolimbic denervation. Brain 2010, 133(Pt 4):1111-1127.
116. Uchiyama M., Isse K., Tanaka K., Yokota N., Hamamoto M., Aida S., et al. Incidental Lewy body disease in patients with REM sleep behaviour disorder. Neurology 1995, 45:709-712.
117. Unger M.M., Moeller J.C., Stiasny-Kolster K., Mankel K., Berg D., Walter U., et al. Assessment of idiopathic rapid-eye-movement sleep behavior disorder by transcranial sonography, olfactory function test, and FP-CIT-SPECT. Movement Disorders 2008, 23(4):596-599.
118. Waseem S., Gwinn-Hardy K. Pain in Parkinson's disease. Common yet seldom recognized symptom is treatable. Postgraduate Medicine 2001, 110(6):33-40.
119. Weisskopf M.G., Chen H., Schwarzschild M.A., Kawachi I., Ascherio A. Prospective study of phobic anxiety and risk of Parkinson's disease. Movement Disorders 2003, 18(6):646-651.
120. Winge K., Fowler C.J. Bladder dysfunction in Parkinsonism: Mechanisms, prevalence, symptoms, and management. Movement Disorders 2006, 21(6):737-745.
121. Wolters E., Braak J. Parkinson's disease: Premotor clinico-pathological correlations. Journal of Neural Transmission 2006, 70:309-319.
122. Zesiewicz T.A., Sullivan K.L., Arnulf I., Chaudhuri K.R., Morgan J.C., Gronseth G.S., et al. Practise parameter: Treatment of nonmotor symptoms of Parkinson's disease. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010, 74:924-931.
123. Zgaljardic D.J., Foldi N.S., Borod J.C. Cognitive and behavioural dysfunction in Parkinson's disease: Neurochemical and clinicopathological contributions. Journal of Neural Transmission 2004, 111:1287-1301.